Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oncorine plus PD-1 mAb in advanced malignant melanoma
ChiCTR2000033959Phase 4Not yet recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Dec 2019
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Oncorine and PD-1 Monoclonal Antibody in melanoma, sponsored by Shanghai Tenth People's Hospital. Primary endpoint: Objective response rate. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
OncorinePD-1 Monoclonal Antibody
03
Conditions
melanoma
Beyond the preview
Go deeper on ChiCTR2000033959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033959.